


PHARMACEUTICAL 2018

FIVE PRIME THERAPEUTICS INC. Rank 84 of 342







PHARMACEUTICAL 2018



FIVE PRIME THERAPEUTICS INC. Rank 84 of 342

The relative strengths and weaknesses of FIVE PRIME THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of FIVE PRIME THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 67% points. The greatest weakness of FIVE PRIME THERAPEUTICS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 179%, being 133% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	311,190
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	50,981
Liabilities, Non-Current	0
Other Assets	2,095
Other Compr. Net Income	-437
Other Expenses	1,798
Other Liabilities	0
Other Net Income	42,486
Other Revenues	0
Property and Equipment	30,762
Research and Development	150,908
Selling, General and Administrative Expense	40,002

Output Variable	Value in 1000 USD
Assets	344,047
Liabilities	50,981
Expenses	192,708
Revenues	0
Stockholders Equity	293,066
Net Income	-150,222
Comprehensive Net Income	-150,440
Economic Capital Ratio	179%

